Vertex, CRISPR’s Casgevy Faces Complex Path to Profitability

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy. Experts weigh in on the path to profit for the treatment and the therapeutic class in general.

Scroll to Top